scholarly journals Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

2004 ◽  
Vol 91 (8) ◽  
pp. 1532-1542 ◽  
Author(s):  
D M Abd El-Rehim ◽  
S E Pinder ◽  
C E Paish ◽  
J A Bell ◽  
R S Rampaul ◽  
...  
2005 ◽  
Vol 129 (10) ◽  
pp. 1277-1282 ◽  
Author(s):  
Mi-Jung Kim ◽  
Gyungyub Gong ◽  
Hee Jae Joo ◽  
Se-Hyun Ahn ◽  
Jae Y. Ro

Abstract Context.—A micropapillary carcinoma (MC) component is generally considered to behave aggressively. Although several reports have described the prognostic significance of MC in breast carcinomas, immunohistochemical findings of MC, especially as compared to non-MC, are rarely described. Objective.—We compared clinicopathologic and immunohistochemical findings between 38 cases of invasive breast carcinoma with an MC component (IMC) and 217 cases of invasive breast carcinoma without an MC component (NIMC). Design.—We constructed a tissue microarray from 38 cases of IMC and performed immunohistochemical stainings for cytokeratin (CK) 7, CK20, estrogen receptor, progesterone receptor, p53, c-Erb-B2, CD34, CK5, epidermal growth factor receptor, and c-Kit in both MC and non-MC components. Results.—Cases with IMC were associated with greater tumor size, more frequent lymphovascular invasion, nodal metastases, greater mean numbers of positive lymph nodes, and higher stage than those with NIMC, but were not associated with poorer survival rates. On immunohistochemistry, only p53 reactivity was statistically different between MC and non-MC components in IMC cases. Estrogen receptor positivity tended to be lower in MC than non-MC, but the difference was not significant. Most of the MCs and non-MCs in IMC cases were positive for CK7, but none of them were positive for CK20, CK5, epidermal growth factor receptor, or c-Kit. Conclusions.—Based on the frequent nodal metastases and association with higher stage found in IMC as compared with NIMC cases, as well as higher p53 positivity and lower frequency of estrogen receptor expression, MC could be considered an aggressive histologic type of breast carcinoma. In both MC and non-MC components in IMC cases, no basallike immunostaining pattern was detected.


2012 ◽  
Vol 72 (10) ◽  
pp. 2657-2671 ◽  
Author(s):  
Catherine A. Del Vecchio ◽  
Kristin C. Jensen ◽  
Ryan T. Nitta ◽  
A. Hunter Shain ◽  
Craig P. Giacomini ◽  
...  

2021 ◽  
Vol 14 (3) ◽  
pp. e239385
Author(s):  
Marte Grønlie Cameron ◽  
Christian Kersten

Neuropathic pain (NP) represents an unmet medical need, where analgesic responses to different epidermal growth factor receptor inhibitors (EGFR-Is) have been described. The human EGFR family of receptors consists of four members (human epidermal growth factor receptor, HER 1–4), signalling via different homodimer and heterodimer combinations. A 52-year-old man was treated with the EGFR-I cetuximab in a trial of severe NP. Pain scores decreased dramatically after blinded cetuximab, but not after placebo. On pain recurrence after the trial, he was prescribed the oral EGFR-Is erlotinib, gefitinib, and lapatinib without relief. However, treatment with the pan-HER-inhibitor afatinib was effective. After 4 years on afatinib, pain control remains excellent with manageable side effects. This is the first reported observation of differential effects of EGFR-Is on NP in the same patient and the first report describing NP relief with afatinib. Further understanding of the underlying pathophysiology could lead to development of EGFR-Is specifically targeting NP.


Sign in / Sign up

Export Citation Format

Share Document